Danaher Past Earnings Performance
Past criteria checks 2/6
Danaher has been growing earnings at an average annual rate of 9.3%, while the Life Sciences industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 5.1% per year. Danaher's return on equity is 7.7%, and it has net margins of 16.6%.
Key information
9.3%
Earnings growth rate
8.6%
EPS growth rate
Life Sciences Industry Growth | 21.5% |
Revenue growth rate | 5.1% |
Return on equity | 7.7% |
Net Margin | 16.6% |
Last Earnings Update | 27 Sep 2024 |
Recent past performance updates
Recent updates
Calculating The Intrinsic Value Of Danaher Corporation (NYSE:DHR)
Dec 26Danaher: A Resilient And Solid Company With Growth Potential
Dec 10Danaher (NYSE:DHR) Seems To Use Debt Quite Sensibly
Dec 08Understanding Danaher's Cautiousness
Oct 25Is There Now An Opportunity In Danaher Corporation (NYSE:DHR)?
Sep 28Danaher Q3 Preview: Market Share Gains In Molecular Testing
Sep 25Is Danaher Corporation (NYSE:DHR) Trading At A 32% Discount?
Sep 12Here's Why Danaher (NYSE:DHR) Can Manage Its Debt Responsibly
Aug 28Danaher: Lofty Price, Bright Future
Aug 22Danaher Corporation's (NYSE:DHR) Price In Tune With Earnings
Aug 13Danaher: Valuation Now Too High Even Compared To Own High Standards
Jul 16What Is Danaher Corporation's (NYSE:DHR) Share Price Doing?
Jun 23Mar Vista - Danaher: Headwinds Are Primarily Cyclical, Growth To Regain Momentum
Jun 20Is Danaher Corporation (NYSE:DHR) Worth US$263 Based On Its Intrinsic Value?
Jun 05Is Danaher (NYSE:DHR) A Risky Investment?
May 21It's Unlikely That Danaher Corporation's (NYSE:DHR) CEO Will See A Huge Pay Rise This Year
May 01Value Vs. Growth? Danaher Says Why Not Both?
Apr 25Danaher: All In On Life Sciences, And Market Update
Mar 27Is Now An Opportune Moment To Examine Danaher Corporation (NYSE:DHR)?
Mar 11Danaher Corporation's (NYSE:DHR) Price Is Out Of Tune With Earnings
Feb 10Bull Case Confirmed: Danaher Is Still One Of The Best Stocks To Buy Long-Term
Jan 30Is Danaher (NYSE:DHR) Using Too Much Debt?
Jan 12My Top 2024 Stock Pick: Danaher
Dec 27Danaher: Poised For Long-Term Growth Despite Near-Term Hurdles
Nov 26RGA Investment Advisors - Danaher: Purity In The Crown Jewel Of Bioprocessing
Nov 19Why Danaher Is One Of My Favorite Long-Term Investments
Oct 26Danaher: Short-Term Headwinds, But Long-Term Tailwinds
Oct 17Should Danaher Investors Sell New Veralto Shares?
Oct 02Danaher: A Lost Year
Aug 30Third Point - Danaher: Don't Be Surprised If Growth Rate Moves To Low Teens
Aug 02Danaher: A Compounding Icon At A Fair Price
Jul 25Danaher: Seizing The Buying Opportunity In A Temporary Bioprocessing Slump
Jun 22Revenue & Expenses Breakdown
How Danaher makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
27 Sep 24 | 23,742 | 3,934 | 7,470 | 1,549 |
28 Jun 24 | 23,568 | 4,056 | 7,358 | 1,528 |
29 Mar 24 | 23,737 | 4,069 | 7,281 | 1,498 |
31 Dec 23 | 23,890 | 4,200 | 7,245 | 1,503 |
29 Sep 23 | 21,026 | 4,408 | 6,080 | 1,332 |
30 Jun 23 | 23,065 | 5,019 | 6,489 | 1,390 |
31 Mar 23 | 24,904 | 5,757 | 6,762 | 1,460 |
31 Dec 22 | 26,643 | 6,222 | 7,080 | 1,528 |
30 Sep 22 | 31,250 | 6,640 | 8,572 | 1,787 |
01 Jul 22 | 30,816 | 6,206 | 8,489 | 1,808 |
01 Apr 22 | 30,283 | 6,206 | 8,369 | 1,803 |
31 Dec 21 | 24,802 | 5,283 | 6,763 | 1,498 |
01 Oct 21 | 28,065 | 5,636 | 7,818 | 1,643 |
02 Jul 21 | 26,720 | 5,361 | 7,543 | 1,544 |
02 Apr 21 | 24,799 | 4,595 | 7,278 | 1,441 |
31 Dec 20 | 22,284 | 3,510 | 6,880 | 1,348 |
02 Oct 20 | 20,392 | 3,083 | 6,354 | 1,246 |
03 Jul 20 | 18,886 | 2,853 | 5,954 | 1,186 |
03 Apr 20 | 18,034 | 2,614 | 5,659 | 1,146 |
31 Dec 19 | 17,911 | 2,364 | 5,577 | 1,126 |
27 Sep 19 | 15,562 | 2,093 | 4,709 | 980 |
28 Jun 19 | 16,037 | 2,145 | 4,880 | 998 |
29 Mar 19 | 16,573 | 2,166 | 5,125 | 1,028 |
31 Dec 18 | 17,049 | 2,406 | 5,356 | 1,059 |
28 Sep 18 | 19,615 | 2,761 | 6,246 | 1,211 |
29 Jun 18 | 19,290 | 2,669 | 6,173 | 1,189 |
30 Mar 18 | 18,819 | 2,553 | 6,072 | 1,160 |
31 Dec 17 | 15,519 | 2,172 | 5,012 | 956 |
29 Sep 17 | 17,828 | 2,360 | 5,764 | 1,098 |
30 Jun 17 | 17,432 | 2,191 | 5,633 | 1,060 |
31 Mar 17 | 17,164 | 2,051 | 5,536 | 1,016 |
31 Dec 16 | 16,882 | 2,153 | 5,481 | 975 |
30 Sep 16 | 16,621 | 1,927 | 5,362 | 943 |
01 Jul 16 | 16,001 | 1,905 | 5,218 | 914 |
01 Apr 16 | 13,663 | 1,775 | 4,549 | 788 |
31 Dec 15 | 14,434 | 1,747 | 4,635 | 861 |
02 Oct 15 | 15,335 | 1,875 | 4,769 | 926 |
03 Jul 15 | 16,530 | 2,177 | 4,865 | 1,002 |
03 Apr 15 | 19,186 | 2,521 | 5,348 | 1,143 |
31 Dec 14 | 12,867 | 1,639 | 3,953 | 769 |
26 Sep 14 | 19,197 | 2,683 | 5,305 | 1,189 |
27 Jun 14 | 19,159 | 2,599 | 5,311 | 1,210 |
28 Mar 14 | 19,336 | 2,583 | 5,405 | 1,267 |
31 Dec 13 | 18,283 | 2,591 | 5,042 | 1,104 |
Quality Earnings: DHR has high quality earnings.
Growing Profit Margin: DHR's current net profit margins (16.6%) are lower than last year (21%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: DHR's earnings have grown by 9.3% per year over the past 5 years.
Accelerating Growth: DHR's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: DHR had negative earnings growth (-11%) over the past year, making it difficult to compare to the Life Sciences industry average (-4.7%).
Return on Equity
High ROE: DHR's Return on Equity (7.7%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/26 04:44 |
End of Day Share Price | 2024/12/26 00:00 |
Earnings | 2024/09/27 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Danaher Corporation is covered by 54 analysts. 26 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
John Eade | Argus Research Company |
Catherine Ramsey Schulte | Baird |
Robert Cornell | Barclays |